|
|
|
| Clinical Comparison of Da Vinci Robot NOSES and Traditional Laparoscopic Surgery for Rectal Cancer |
| LIU Jun, LI Taiyuan, ZHU Renfang, LIU Xianwei |
| First-author's address: Jiujiang NO.1 People's Hospital, Jiangxi Province, Jiujiang 332000, China |
|
|
|
|
Abstract Objective: To explore the clinical comparison between the natural orifice specimen extraction endoscopic surgery (NOSES) with Da Vinci robot and the traditional laparoscopic surgery for rectal cancer. Method: A total of 120 patients with rectal cancer who were admitted to Jiujiang NO.1 People's Hospital and the First Affiliated Hospital of Nanchang University from November 2020 to November 2021 were selected as the research objects, and were divided into the observation group and the control group by random number table method, with 60 cases in each group. The control group was treated with traditional laparoscopic surgery, and the observation group was treated with the Da Vinci robot NOSES. The relevant clinical indicators and complications were compared between the two groups. Result: The operation time of the observation group was longer than that of the control group, the hospitalization cost was lower than that of the control group, the amount of intraoperative bleeding was less than that of the control group, and the anus preservation rate of low rectal cancer was higher than that of the control group, the differences were statistically significant (P<0.05); there were no differences between the observation group and the control group in urine volume and number of lymph node dissection during operation (P>0.05). The exhaust time, fluid intake time and catheter removal time in the observation group were shorter than those in the control group (P<0.05). There was no difference in hospitalization time between the observation group and the control group (P>0.05). There was no difference in the incidence of complications between the observation group and the control group (P>0.05). Conclusion: The Da Vinci robot NOSES treatment is considered for patients with rectal cancer, which has the advantages of less blood loss and faster rehabilitation.
|
|
Received: 13 December 2022
|
|
|
|
|
|
|
